GENE ONLINE|News &
Opinion
Blog

2022-05-24|

Convergence, Communication and Commercialization, The Cornerstones In Emerging Regulatory Trends

by Arvind C. Shekhar
Share To
photo credit to ASCGT

At the recently concluded 25th annual meeting of the American Society for Gene and Cell Therapy (ASGCT), Dr. Peter Marks, Director, Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration and Dr. Ana Hidalgo-Simon, Head of Advanced Therapies, European Medicines Agency took part in a Fireside chat titled “State of the Field: Emerging Regulatory Trends”. The session was aimed at creating greater awareness about how the two main regulatory agencies (USFDA and EMA) are gearing to regulate the field of cell and gene therapy. In the freewheeling conversation the speakers shared their insights on various aspects ranging from importance of public-private partnerships, lessons learned from COVID-19 to the role of innovative trial design and primary biomarkers in accelerated development of gene therapies. 

 

Role of Public-Private Partnerships In Cell And Gene Therapies

 

GO Prime with only $1.49 now

LATEST
Regeneron Steps In to Rescue 23andMe From Bankruptcy With $256M Acquisition
2025-05-20
Virtual trial shows combo rescue inhaler nearly halves severe asthma attacks
2025-05-20
Lunit Surpasses 1 Million Mammograms in U.S. One Year After Volpara Acquisition
2025-05-19
The Fight Against Hard-to-Treat Cancers : Bold Bets on a Multifaceted Approach
2025-05-19
CRISPR Makes History with First One-of-a-Kind Gene Therapy for Infant
2025-05-19
VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025
2025-05-15
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
EVENT
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
2025-06-16
US BIO International Convention
Boston, U.S.A.
Scroll to Top